Ethylene

Ethylene

SCHEMBL76403

C=C.C=C.C=C.Nc1nc(N)nc(N)n1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
CASP1 P29466 1/20 0.44
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
POLB P06746 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2B P29275 1/20 0.38
CYP1A2 P05177 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
KDM4E B2RXH2 3/20 0.32
ALOX15 P16050 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HSP90AB1 P08238 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL11150398 1.00 LMNA (0.47) LMNACASP1ADORA2AADORA1POLB
Ethylene SCHEMBL2038444 1.00 LMNA (0.47) LMNACASP1ADORA2AADORA1POLB
Ethylene SCHEMBL3132468 0.95 LMNA (0.45) LMNACASP1ADORA2AADORA1POLB
SCHEMBL29485005 0.89
SCHEMBL9583239 0.89 CASP1 (0.50) LMNACASP1ADORA2AADORA1POLB
SCHEMBL25853 0.89
SCHEMBL8465809 0.89 CASP1 (0.50) LMNACASP1ADORA2AADORA1POLB
SCHEMBL9579151 0.89 CASP1 (0.50) LMNACASP1ADORA2AADORA1POLB
SCHEMBL29876207 0.89
SCHEMBL29900242 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275946-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2025-09-04 US claimed
US-12325755-B2 Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-10 US claimed
US-20240203601-A1 ANALYZING COPY NUMBER VARIATION IN THE DETECTION OF CANCER VERINATA HEALTH, INC. 2024-06-20 US claimed
EP-3383920-B1 TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN UNIV CALIFORNIA (US) 2024-01-10 EP claimed
US-20230383005-A1 ANTI-CD46 ANTIBODIES AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-30 US claimed
WO-2022169634-A9 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-09-22 WO claimed
US-11447563-B2 Tumor selective macropinocytosis-dependent rapidly internalizing antibodies THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-09-20 US claimed
US-11434301-B2 Anti-CD46 antibodies and methods of use THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-09-06 US claimed
WO-2022169634-A1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER UNM RAINFOREST INNOVATIONS (US) 2022-08-11 WO claimed
US-11219697-B2 Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-01-11 US claimed
WO-2006027231-A1 METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH INGENIUM PHARMACEUTICALS AG (DE) 2006-03-16 WO claimed
WO-2006018316-A1 METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH INGENIUM PHARMACEUTICALS AG (DE) 2006-02-23 WO claimed
WO-2006002902-A2 METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH INGENIUM PHARMACEUTICALS AG (DE) 2006-01-12 WO claimed
WO-2005107447-A2 METHODS FOR THE PRODUCTION OF IMPROVED LIVE STOCKS AND DISEASE MODELS FOR THERAPEUTIC RESEARCH INGENIUM PHARMACEUTICALS AG (DE) 2005-11-17 WO claimed
EP-1088055-A4 ALLELIC SERIES OF GENOMIC MODIFICATIONS IN CELLS UNIV CASE WESTERN RESERVE (US) 2005-10-19 EP claimed
US-20040180955-A1 Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy AU JESSIE L-S (US) 2004-09-16 US claimed
EP-1429713-A2 METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY Au, Jessie L.S. (US) 2004-06-23 EP claimed
WO-2003026574-A2 METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY AU JESSIE L-S (US) 2003-04-03 WO claimed
EP-1088055-A1 ALLELIC SERIES OF GENOMIC MODIFICATIONS IN CELLS Case Western Reserve University (US) 2001-04-04 EP claimed
WO-1999067361-A1 ALLELIC SERIES OF GENOMIC MODIFICATIONS IN CELLS CASE WESTERN RESERVE UNIVERSITY (US) 1999-12-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11219697-B2 Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration CTSS, CTSK, CTSF LMNA 2373/4885CASP1 84/4885ADORA2A 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.